- Home
- HCICU vs SCLXW Comparison
HCICU vs SCLXW Comparison
Compare HCICU & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCICU | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | HCICU | SCLXW |
|---|---|---|
| Price | $10.07 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.8K | ★ 5.0K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $9.80 | $0.05 |
| 52 Week High | $10.27 | $0.64 |
Technical Indicators
Market Signals| Indicator | HCICU | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 70.49 | 46.75 |
| Support Level | $10.01 | $0.11 |
| Resistance Level | $10.27 | $0.18 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 27.78 | 74.71 |
Price Performance
Historical ComparisonAbout HCICU Hennessy Capital Investment Corp. VIII Units
Hennessy Capital Investment Corp VIII is a blank check company.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.